Search Clinical Trials
By Condition
By Location (USA)
By Location (Other)
By Sponsor
Resources
Privacy Policy
About Us
Disclaimer
12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified medical advice, visits or professional assistance with a genuine dr.. We are not doctors. Always consult your mD about 12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. 12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder Clinical research trials and 12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder medical trials take place in many of places throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectiveness of new does drugs. The purpose of the studies / projects is to solve specific human healthcare questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to find cures for all varieties of conditions, like 12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder. 12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder Clinical Trials and other clinical trials allow for volunteers to have health treatment options before they are available to the masses. Many times the human subjects acquire professional assistance for free of charge, and sometimes they are compensated for their time. Occasionally there is a cost for a 12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder clinical trial. Test subjects typically obtain the finest healthcare available for their 12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder condition. Dangers are a reality, nevertheless, and might include additional or frequent doctor trips, medical dangers (possibly life-jeopardising), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials patients.

Home > "1" Clinical Trials Conditions > 12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder

12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder



12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder

For Condition: chronic myeloproliferative disorders,plasma cell neoplasm,myelodysplastic and myeloproliferative diseases,Leukemia,Lymphoma
Status: Recruiting
Sponsor(s): Cancer Institute of New Jersey , National Cancer Institute (NCI)
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of 12-O-tetradecanoylphorbol-13-acetate in treating patients who have hematologic cancer or bone marrow disorder that has not responded to previous treatment.
Details: OBJECTIVES: - Determine the maximum tolerated dose and dose limiting toxicity of 12-O-tetradecanoylphorbol-13-acetate (TPA) in patients with relapsed or refractory hematologic malignancies or bone marrow disorders. - Determine the pharmacokinetics of TPA in these patients. - Determine the effects of TPA on the cellular composition of blood and bone marrow in these patients. OUTLINE: This is a dose-escalation study. Patients receive 12-O-tetradecanoylphorbol-13-acetate (TPA) IV over 1 hour on days 1 and 8 followed by 2 weeks of rest. Courses repeat in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of TPA until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which no more than 1 of 6 patients experiences dose limiting toxicity. PROJECTED ACCRUAL: Approximately 36 patients will be accrued for this study.
Eligibility:
Study Type:
  Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically proven relapsed or refractory hematologic malignancy or bone marrow disorder for which there is no standard curative therapy, including, but not limited to: - Myelodysplasia - Multiple myeloma - Myeloproliferative syndrome - Chronic lymphocytic leukemia - Aplastic anemia - Non-Hodgkin's lymphoma - Acute leukemia - Hodgkin's lymphoma - Chronic myelogenous leukemia PATIENT CHARACTERISTICS: Age: - Over 18 Performance status: - ECOG 0-2 Life expectancy: - Greater than 1 month Hematopoietic: - Not specified Hepatic: - Bilirubin no greater than 1.5 times upper limit of normal (ULN) - AST no greater than 3 times ULN Renal: - Creatinine no greater than 2.0 mg/dL Cardiovascular: - Cardiac ejection fraction greater than 40% Pulmonary: - FEV_1 greater than 50% predicted Other: - No active infection - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception during and for 10 weeks after study participation - No uncontrolled psychiatric or medical illness PRIOR CONCURRENT THERAPY: Biologic therapy: - Greater than 3 weeks since prior biologic therapy Chemotherapy: - Greater than 3 weeks since prior chemotherapy and recovered Endocrine therapy: - Not specified Radiotherapy: - Not specified Surgery: - Not specified Other: - No other concurrent investigational agents
Total Enrollment: 

Location and Contact Information:

Overall Study Official:
RogerStrair,  Study Chair,  Cancer Institute of New Jersey

Cancer Institute of New Jersey *Recruiting*
New Brunswick,  New Jersey,  08901
United States
Recruiting Roger  Strair 732-235-6044


Additional Information:
Study ID Numbers:
  CDR0000067255;  CINJ-059806,UMDNJ-2716,NCI-G99-1573
Study Start Date: 
Record last reviewed: November 1999
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00004058

Other Chronic Myeloproliferative Disorders Studies:
1. Sirolimus in Preventing Graft-Versus-Host Disease in Patients With Hematologic Malignancies Who Are Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

2. T-Cell-Depleted Allogeneic Stem Cell Transplantation Followed By Treated Donor T Cells After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies

3. Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies

4. Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia

5. Donor Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Related Studies:

Other chronic myeloproliferative disorders Clinical Trials
Other New Jersey Clinical Trials
Other New Brunswick Clinical Trials

12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder

Modify your Search

  Other chronic myeloproliferative disorders Clinical Trials
  Other New Jersey Clinical Trials
  Other New Brunswick Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103